NASDAQ:AMRI - Albany Molecular Research Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$21.74 0.00 (0.00 %)
(As of 06/20/2018 12:11 PM ET)
Previous Close$21.74
Today's RangeN/A
52-Week Range$13.01 - $22.17
VolumeN/A
Average Volume872,120 shs
Market Capitalization$937.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
Albany Molecular Research logoAlbany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Receive AMRI News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:AMRI
CUSIPN/A
Phone+1-518-4640279

Debt

Debt-to-Equity Ratio0.62
Current Ratio0.68
Quick Ratio0.37

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-5.93%
Return on Equity-13.39%
Return on Assets-3.42%

Miscellaneous

Employees3,085
Outstanding Shares43,120,000

Albany Molecular Research (NASDAQ:AMRI) Frequently Asked Questions

What is Albany Molecular Research's stock symbol?

Albany Molecular Research trades on the NASDAQ under the ticker symbol "AMRI."

How were Albany Molecular Research's earnings last quarter?

Albany Molecular Research, Inc. (NASDAQ:AMRI) issued its earnings results on Tuesday, May, 10th. The biotechnology company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.21 by $0.14. The biotechnology company earned $102.80 million during the quarter, compared to analyst estimates of $107.20 million. Albany Molecular Research had a negative net margin of 5.93% and a negative return on equity of 13.39%. View Albany Molecular Research's Earnings History.

Who are Albany Molecular Research's key executives?

Albany Molecular Research's management team includes the folowing people:
  • William S. Marth, President, Chief Executive Officer, Director
  • Felicia Ladin, Chief Financial Officer, Senior Vice President, Treasurer
  • Lori M. Henderson Esq., Senior Vice President, General Counsel, Secretary
  • Christopher M Conway, Senior Vice President - Discovery and Development and Global Commercial Sales
  • , Bio & Compensation - 
  • Milton Boyer, Senior Vice President - Drug Product Manufacturing
  • , Bio & Compensation - 
  • Steven R. Hagen Ph.D., Senior Vice President - Manufacturing and Pharmaceuticals
  • George Svokos, Chief Commercial Officer and Senior Vice President, API
  • Jimmy Wang Ph.D., Chief Information Officer
  • , Bio & Compensation - 
  • Thomas E. D' Ambra Ph.D., Non-Executive Chairman of the Board
  • David H. Deming, Director

Has Albany Molecular Research been receiving favorable news coverage?

News headlines about AMRI stock have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Albany Molecular Research earned a media sentiment score of 0.12 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Albany Molecular Research?

Shares of AMRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Albany Molecular Research's stock price today?

One share of AMRI stock can currently be purchased for approximately $21.74.

How big of a company is Albany Molecular Research?

Albany Molecular Research has a market capitalization of $937.41 million. Albany Molecular Research employs 3,085 workers across the globe.

How can I contact Albany Molecular Research?

Albany Molecular Research's mailing address is 21 Corporate Cir, PO Box 15098, ALBANY, NY 12203-5154, United States. The biotechnology company can be reached via phone at +1-518-4640279.


MarketBeat Community Rating for Albany Molecular Research (AMRI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about Albany Molecular Research and other stocks. Vote "Outperform" if you believe AMRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.